目的 ·探讨瑞舒伐他汀钙对慢性阻塞性肺疾病（COPD）不同高分辨CT（HRCT）表型的疗效。方法 ·随机抽取COPD患者50例，通过对HRCT下的不同肺气肿和支气管壁增厚的表现，分成A、E、M 3型。在常规治疗的基础上，予以瑞舒伐他汀钙干预，5 mg/d，为期2年。于治疗开始前行胸部HRCT，进行分型；治疗前后检测患者血浆中的白介素6（IL-6）和白介素8（IL-8），以及肺功能。结果 · 50例COPD患者中，A型10例，E型17例，M型23例。3型患者IL-6、IL-8、用力肺活量（FVC）和第1秒用力呼气容积(FEV1)治疗前后差异均有统计学意义（均P＜0.05）。3型间行单因素方差分析，IL-6、IL-8的下降幅度差异均有统计学意义
（P=0.035，P=0.006），A型下降幅度最大；FVC和FEV1的下降幅度差异无统计学意义（P=0.154，P=0.453）。结论 ·瑞舒伐他汀钙对不同HRCT表型的COPD患者的全身炎症反应均有一定疗效，但对肺功能未观察到改善作用；不同表型间疗效有所差异。

Objective · To investigate the efficacy of rosuvastatin calcium for different high-resolution CT (HRCT) phenotypes of COPD. Methods · Fifty COPD patients were randomly selected and stratified into 3 types, i.e. A, E, M according to emphysema and bronchial wall thickening using HRCT. Based on conventional treatment, patients received 5 mg/d of rosuvastatin calcium for 2 years. Chest HRCT and type stratification were performed prior to treatment. Plasma IL-6 and IL-8 levels and lung function were measured before and after treatment. Results · There were 10 cases of A type, 17 cases of E type, and 23 cases of M type. Differences in IL-8, IL-6, FVC, and FEV1 before and after treatment between 3 types of patients were statistically significant (P < 0.05). Univariate variance analysis showed that differences in the decrease of IL-6 and IL-8 were statistically significant (P = 0.035, P = 0.006), which in A type patients decreased most. The differences in the decrease of FVC and FEV1 were not statistically significant (P=0.154, P = 0.453). Conclusion · Rosuvastatin calcium had efficacy for systemic inflammatory response in COPD patients with different HRCT phenotypes, but was unable to improve pulmonary function. The efficacy for different phenotypes varied.